DOI: 10.5176/2345-783X_PHARMA17.36
Authors: Liz Milward, Baharudin Ibrahim
Abstract:
The new fields of pharmacogenomics and pharmacometabolomics provide complementary information that can be used to predict and assess patients responses to drugs, based on individual genomic variants and on biomarkers of drug response or toxicity in biofluids, respectively. The panel will first consider the emerging area of complex pharmacogenomics, which looks at real-world interactive situations involving multiple drugs and genomic factors, for various drugs widely used to treat common conditions such as cancer, arthritis and depression. The panel will then go on to consider how pharmacometabolomics can best be used to evaluate and complement pharmacogenomics. One important advantage of combining these approaches is that while pharmacogenomics makes probability-based predictions of drug responses, other factors besides genomics may influence the actual response. Pharmacometabolomics can help assess how well pharmacogenomics performs in different individuals and improve prediction of treatment responses, as well as providing information on metabolic pathways and other non-genetic factors involved in patient responses. The panel will address key challenges that need to be met in fusing these two approaches for translation into clinical practice to improve drug safety and efficacy and achieve the optimal outcomes for patients.
Keywords: genomics, multifactorial drug-gene interactions, metabolomics, metabonomics, personalized health care, precision medicine
Updating...